22322-Lung Cancer-NA-1619

Lung Cancer

SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >= 50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression (J3M-MC-JZQB)

  • Details

ClinicalTrials.gov ID: NCT06119581
Diagnosis Type: NA
USOR Number:

  • Address


,
P:

Search by practice name, trial titles, indicators and specific disease types.